Syncor retools supplier alliances

Article

Radiopharmacy firm Syncor last week announced changes in its relationships with suppliers AmershamMedi-Physics and Du Pont Merck Pharmaceutical that will affectthe company's 1995 financial performance. Syncor, of Chatsworth,CA, said that Medi-Physics has

Radiopharmacy firm Syncor last week announced changes in its relationships with suppliers AmershamMedi-Physics and Du Pont Merck Pharmaceutical that will affectthe company's 1995 financial performance. Syncor, of Chatsworth,CA, said that Medi-Physics has stopped selling its radiopharmaceuticalproducts through Syncor's network. The decision was effectiveJan. 16 and is due to a distribution alliance Medi-Physics formedlate last year with Mallinckrodt Medical and Geodax Technologies(SCAN 12/28/94). Syncor earned about $2.4 million in operatingincome from sales of Medi-Physics products in 1994.

On a positive note, Syncor has restructured its distributionrelationship with Du Pont Merck, which the companies entered intolast year (SCAN 1/19/94). The costs of the alliance have provedhigher than expected and have reduced Syncor's margins from the30% range to 20%, according to the company. As a result, Syncorand Du Pont Merck restructured their pricing agreement to evenout the costs of distribution. The alliance was responsible for$64 million in new sales last year, Syncor reported.

Also under the terms of the alliance, Syncor began distributingDu Pont Merck's Neurolite product, which received Food and DrugAdministration approval last year (SCAN 12/14/94). Syncor haspreferential distribution rights for the brain SPECT imaging agent.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.